Search

4 result(s) for 'author#"Geert Jan Groeneveld"' within BMC

1. 19th biennial IPEG Meeting

   Authors: Igor Timofeev, Leon Kenemans, P. F. Fabene, A. Ahnaou, Sebastian Olbrich, Robert Oostenveld, Martijn Arns, Nash Boutros, Fernando Lopes da Silva, Igor Timofeev, Ole Jensen, Sandra K. Loo, Hans-Peter Landolt, Jan Mathijs Schoffelen, Alida A. Gouw, Arjan Hillebrand…

   Citation: Neuropsychiatric Electrophysiology 2016 2(Suppl 1):8

   Content type: Meeting abstracts

   Published on: 29 November 2016

   This article is part of a Supplement: Volume 2 Supplement 1

   • View Full Text
   • View PDF

2. Quantification of tremor using consumer product accelerometry is feasible in patients with essential tremor and Parkinson’s disease: a comparative study

   To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer produc...

   Authors: Emilie M. J. van Brummelen, Dimitrios Ziagkos, Wadim M. I. de Boon, Ellen P. Hart, Robert J. Doll, Teppo Huttunen, Petteri Kolehmainen and Geert Jan Groeneveld

   Citation: Journal of Clinical Movement Disorders 2020 7:4

   Content type: Research article

   Published on: 7 April 2020

   • View Full Text
   • View PDF

3. Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M₁ receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

   The cholinergic system and M₁ receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M₁ receptor partial agonist HTL0018318 is under development for the symptomatic ...

   Authors: Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert Jan Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld and Pradeep J. Nathan

   Citation: Alzheimer's Research & Therapy 2021 13:87

   Content type: Research

   Published on: 21 April 2021

   • View Full Text
   • View PDF

4. Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

   To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we inv...

   Authors: Jolien F. Leijenaar, Geert Jan Groeneveld, Erica S. Klaassen, Anna E. Leeuwis, Philip Scheltens, Henry C. Weinstein, Joop M. A. van Gerven, Frederik Barkhof, Wiesje M. van der Flier and Niels D. Prins

   Citation: Alzheimer's Research & Therapy 2020 12:10

   Content type: Research

   Published on: 7 January 2020

   • View Full Text
   • View PDF